Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 29:jiac270. doi: 10.1093/infdis/jiac270

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For cipermissions, please e-mail: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 1. — (A)Absolute anti-receptor biding domain (RBD) immunoglobulin (Ig)G concentrations in cord blood compared with maternal sera according to presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) placental injury. All maternal sera and 83% (n = 19) cord blood samples had detectable anti-RBD IgG. There was no statically significant difference in the absolute cord blood anti-RBD IgG concentrations in patients with and without SARS-CoV-2-induced placental injury (log end dilution titer 2.7 [interquartile range {IQR}, 1.8–3.6] vs 2.7 [IQR, 2.4–2.9], P = .59). (B) Anti-SARS-CoV-2 RBD IgG cord-to-maternal ratios grouped according to presence of SARS-CoV-2 placental injury. The cord, maternal ratio, or transplacental transfer efficiency was calculated as the ratio between cord blood and maternal anti-RBD IgG log endpoint titers. The median antibody transfer efficiency in placentas without SARS-CoV-2-induced placental injury was 0.77 (IQR, 0.61–0.97). The median antibody transfer efficiency in placentas with SARS-CoV-2-induced placental injury was 0.97 (IQR, 0.80–1.01; P = .05).